Skip to main content
Clinical Trials/NCT03239418
NCT03239418
Terminated
Not Applicable

A Novel Treatment Using Neuromuscular Electrical Stimulation to Improve Eyelid Function in Patients With CN III and CN VII Palsy.

Brooks Rehabilitation1 site in 1 country26 target enrollmentJanuary 6, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Blepharoptosis
Sponsor
Brooks Rehabilitation
Enrollment
26
Locations
1
Primary Endpoint
Marginal reflex distance-1 (MRD-1)
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

Traumatic brain injury, stroke and other neurological conditions may result in weakness of the muscles that either open or close the eye. This is generally a result of impaired functioning of the oculomotor or facial cranial nerves. Current treatments to improve eye opening or closing are either invasive or largely ineffective. This study tests a noninvasive means of improving eyelid opening and closing by applying a previously demonstrated safe and effective neuromuscular electrical stimulation (NMES) intervention to the muscles controlling eyelid movement. Participants in this study will either receive the investigational NMES protocol 30 min per day for five days or a sham NMES for the same period. The primary outcome for this study is the participants' ability to open or close their affected eye. Secondary outcomes include additional measures of eye and corneal health.

Registry
clinicaltrials.gov
Start Date
January 6, 2017
End Date
October 16, 2019
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Cranial nerve III (oculomotor nerve) and/or cranial nerve IV (facial nerve) palsy.
  • Able to read and communicate in English.

Exclusion Criteria

  • Idiopathic onset of CN III and/or CN IV palsy.
  • Traumatic injury to the eye or eyelid.
  • Active wounds in the treatment area.
  • Presence of swelling or infection in or surrounding the affected eye.
  • Diminished sensation in the area to be treated.

Outcomes

Primary Outcomes

Marginal reflex distance-1 (MRD-1)

Time Frame: Within 1 week of last treatment session.

Measure of eyelid function for participants with CN III or CN VII palsy

Palpebral fissure height

Time Frame: Within 1 week of last treatment session.

Measure of eyelid function for participants with CN III or CN VII palsy

Secondary Outcomes

  • Upper eyelid crease distance(Within 1 week of last treatment session.)
  • World Health Organization Quality of Life - BREF (WHOQOL-BREF)(Within 1 week of last treatment session.)

Study Sites (1)

Loading locations...

Similar Trials